incretin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-16 and is reviewed periodically as new material appears.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| 分子类别 | 合成多肽 | 含非天然氨基酸与脂肪酸侧链 |
| 分子量 | 约 4.7 kDa | 多肽量级，精确值随计法而异 |
| 外观 | 白色至类白色冻干粉 | 常见冻干形态，供复溶使用 |
| 溶解性 | 易溶于水 | 复溶后为澄清至微乳光液体 |
| 常见同义词 | LY3437943 | 开发阶段使用的代号 |
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
== See also == Trade Incense trade route, a large network around the Mediterranean and beyond Land of Frankincense (Frankincense Trail), site in Oman Nabataeans, a trader tribe Literature Desi Sangye Gyatso, author of a Tibetan herbal Historia Plantarum (Theophrastus book) Similar plants and products Agarwood Benzoin (resin) Copal Elemi, resin or tree Myrrh, resin Palo santo (Bursera graveolens), tree Pistacia lentiscus (mastic tree), and Mastic (plant resin)
Those coming from a minority background often receive lower quality care, they are less likely to get anti-AD medications compared to their White counterparts. Furthermore, when they are prescribed medication, they are less likely to adhere to the treatment due to various factors and barriers such as the quality of interaction with healthcare providers, distrust in doctors, worries about retaining personal autonomy, stigmas and different beliefs.
== History == The incidence of acute rheumatic fever and rheumatic heart disease is not declining. Recent figures quote the incidence of Acute Rheumatic Fever as 0.6–0.7/1,000 population in the United States and Japan compared with 15–21/1,000 population in Asia and Africa. The prevalence of Acute Rheumatic Fever and Sydenham's Chorea has declined progressively in developed countries over the last decades.
Sources: en.wikipedia.org
=== Synthetic polymers === ECD studies of polyalkene glycols, polyamides, polyacrylates and polyesters are useful for understanding composition of polymer samples. It has become a powerful technique to analyze structural information about precursor ions during MS/MS for synthetic polymers. ECD's single bond cleavage tendency makes the interpretation of product ion scans simple and easy for polymer chemistry.
. Effectively the same result can be found in the original work by Kermack and McKendrick. These solutions may be easily understood by noting that all of the terms on the right-hand sides of the original differential equations are proportional to
=== April === 1 April: The minimum wage rises by 1.5% from $23.15 to $23.50. In addition, training and starting wages rise to $18.80. The Queenstown Lakes District Council strips Councillor Niki Gladding of her roles after she leaked plans by the Council to dump treated effluent into the Shotover River. 3 April – The New Zealand Parliament passes legislation repealing Section 7AA of the Oranga Tamariki Act 1989, which requires Oranga Tamariki (the Ministry of Children) to work in partnership with Māori iwi (tribes) and hapū (sub-groups). 4 April: The Financial Markets Authority commences civil proceedings against insurance company IAG New Zealand for overcharging about 239,000 customers $35 million by incorrectly pricing premiums over the past two decades. The New Zealand Parliament's Justice select committee recommends that the ACT party's contentious Treaty Principles Bill not proceed further following substantial public feedback. The Royal New Zealand Navy's court of inquiry concludes that a series of human errors led to the sinking of HMNZS Manawanui (2019) in early October 2024. 6 April – Several Greenpeace New Zealand protesters occupy part of Port Taranaki to prevent an Indonesian ship carrying palm kernel from unloading. Police arrest four protesters. 7 April: A bomb threat leads to the disruption of proceedings at the Wellington and Palmerston North district courts.
=== Machine Learning Force Fields === Machine Learning Force Fields (MLFFs) represent one approach to modeling interatomic interactions in molecular dynamics simulations. MLFFs can achieve accuracy close to that of ab initio methods. Once trained, MLFFs are much faster than direct quantum mechanical calculations. MLFFs address the limitations of traditional force fields by learning complex potential energy surfaces directly from high-level quantum mechanical data. Several software packages now support MLFFs, including VASP and open-source libraries like DeePMD-kit and SchNetPack.
Sources: en.wikipedia.org
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。
天然肽类在体内容易被酶解并快速清除。脂肪酸侧链与非天然氨基酸可以延缓清除、降低酶解速率。修饰后的分子因此更适合较长间隔的给药安排。
公开资料主要来自临床阶段的报告与注册平台记录。这些材料提供的是阶段性信息，而非最终结论。完整的安全性与有效性数据仍在积累中。
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.